Free Trial
→ Trump Knows Exactly What He's Doing (From Brownstone Research) (Ad)
NASDAQ:VERU

Veru Q4 2023 Earnings Report

Veru logo
$0.51 -0.02 (-3.67%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$0.52 +0.01 (+2.32%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Veru EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Veru Revenue Results

Actual Revenue
$3.86 million
Expected Revenue
$3.95 million
Beat/Miss
Missed by -$90.00 thousand
YoY Revenue Growth
N/A

Veru Announcement Details

Quarter
Q4 2023
Date
12/8/2023
Time
N/A
Conference Call Date
Friday, December 8, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Veru's Q3 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Veru's Q4 2023 Press ReleasePress Release
(8-K)
Veru's Q4 2023 Annual reportAnnual report
(10-K)

Veru Earnings Headlines

Muscle-sparing obesity drug safe for Phase 3 trial, Veru says
May 28 at 11:32 PM | yahoo.com
Veru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with Semaglutide
May 28 at 6:55 AM | quiverquant.com
Elon Musk’s Frightening Warning Forces Trump’s Hand
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.
May 30, 2025 | American Hartford Gold (Ad)
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
May 28 at 6:30 AM | globenewswire.com
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom
May 26, 2025 | seekingalpha.com
Youngsters at Dunstable school hear about the dangers of knife crime
May 22, 2025 | msn.com
See More Veru Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veru? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veru and other key companies, straight to your email.

About Veru

Veru (NASDAQ:VERU), a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

View Veru Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles